A 24-Month Study to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Participants With Early Alzheimer's Disease (MissionAD1)
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease
Sponsor: Biogen
Terminated
Due to an unfavorable risk-benefit ratio including no evidence of potential efficacy, and the adverse event profile of E2609 being worse than placebo.
A PHASE3 clinical study on Alzheimer's Disease, this trial is terminated or withdrawn. The trial is conducted by Biogen and has accumulated 22 data snapshots since 2016. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
22 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE3
-
Dec 2021 — Jul 2024 [monthly]
Terminated PHASE3
-
Mar 2021 — Dec 2021 [monthly]
Terminated PHASE3
Status: Active Not Recruiting → Terminated
▶ Show 17 earlier versions
-
Jan 2021 — Mar 2021 [monthly]
Active Not Recruiting PHASE3
-
Mar 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE3
-
Oct 2019 — Mar 2020 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Aug 2019 — Oct 2019 [monthly]
Recruiting PHASE3
-
Jul 2019 — Aug 2019 [monthly]
Recruiting PHASE3
-
Jun 2019 — Jul 2019 [monthly]
Recruiting PHASE3
-
Feb 2019 — Jun 2019 [monthly]
Recruiting PHASE3
-
Jan 2019 — Feb 2019 [monthly]
Recruiting PHASE3
-
Oct 2018 — Jan 2019 [monthly]
Recruiting PHASE3
-
Aug 2018 — Oct 2018 [monthly]
Recruiting PHASE3
-
Jul 2018 — Aug 2018 [monthly]
Recruiting PHASE3
-
Jun 2018 — Jul 2018 [monthly]
Recruiting PHASE3
-
Jan 2018 — Jun 2018 [monthly]
Recruiting PHASE3
-
Dec 2017 — Jan 2018 [monthly]
Recruiting PHASE3
-
Apr 2017 — Dec 2017 [monthly]
Recruiting PHASE3
-
Feb 2017 — Apr 2017 [monthly]
Recruiting PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE3
First recorded
Oct 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Biogen
- Eisai Co., Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Aberdeen, United Kingdom , Amherst, United States , Anjo-shi, Japan , Athens, Greece , Atlanta, United States , Atlantis, United States , Austin, United States , Aventura, United States , Barcelona, Spain , Bath, United Kingdom and 194 more locations